Should You Buy Fractyl Health, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Fractyl Health, Inc. (GUTS) presents a moderate quality profile with a QOC score of 4.2/10. Trading at $0.57, separating genuine undervalued opportunities from value traps is essential, as detailed by our model data.
The short answer: 1 of 2 CirclFi valuation models project upside for Fractyl Health, Inc. (GUTS) at $0.56 — the models are evenly split, with a Quality Score of 4.2/10 and Value-Trap risk of 17/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Fractyl Health, Inc. (GUTS) in 2026?
What Is the Bull Case vs the Bear Case for Fractyl Health, Inc. (GUTS)?
| Bull case — $0.60 target (+6.5%) | Bear case — $0.32 target (-43.3%) |
|---|---|
| Industry tailwind: partnership and licensing deals could provide meaningful support for Fractyl Health, Inc.'s revenue and margin trajectory in the Biotechnology space. | According to the CirclFi Quality of Company (QOC) framework, Fractyl Health, Inc.'s rating of 4.2/10 indicates below-average quality, raising questions about sustainable earnings levels. |
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model sees the stock as overvalued with a fair value of $0.32 (-43.3%), suggesting that the market price embeds overly optimistic growth assumptions. | |
| Industry headwind: binary clinical trial outcomes represents a meaningful risk for Fractyl Health, Inc. and its Biotechnology peers. |
How Does GUTS Compare to Its Biotechnology Peers?
Valuation data pages: CRBP · DCOY · INDP · PALI · ENVB · SANA · TGTX · TRDA · LXEO · EXEL · INCY
Which Other Stocks Score Like GUTS on Quality?
Closest companies to GUTS’s Quality of Company score of 4.2/10, across all industries.
Which Biotechnology Screens Does GUTS Appear In?
So Is Fractyl Health, Inc. (GUTS) Worth Buying in 2026?
Our models don't have a clear verdict on Fractyl Health, Inc.. At $0.57 vs. $0.46 median fair value, the median upside of -18.4% masks significant model disagreement (+49.8% spread). With quality at 4.2/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Fractyl Health, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About GUTS Stock?
Should I buy GUTS stock right now?
Based on CirclFi's multi-model analysis, 1 of 2 models see upside for GUTS at $0.56. The models are divided, which means the investment case depends heavily on your assumptions about Fractyl Health, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Fractyl Health, Inc.?
Key risks include: a below-average Quality Score of 4.2/10, indicating fundamental weakness; limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does GUTS compare to its competitors?
Among Biotechnology peers, GUTS holds a Quality Score of 4.2/10. Comparable companies include CRBP (QOC 4.3), DCOY (QOC 4.2), INDP (QOC 4.3). The relative ranking helps investors identify whether GUTS offers better fundamental quality than alternatives in the same sector.
Is GUTS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. GUTS's Quality Score of 4.2/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy GUTS at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $0.32 to $0.60. At $0.56, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for GUTS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad